NANOPARTICLE-BASED DRUG DELIVERY AND DRUG REPURPOSING STRATEGIES FOR PARKINSON'S DISEASE: OVERCOMING BLOOD–BRAIN BARRIER CHALLENGES
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Parkinson's Disease is considered as a neurodegenerative disorder and is identified by the deterioration of the motor functions due to loss of the dopamine releasing neurons. Due to this dementia occurs which is characterised by forgetfulness and impairment in cognitive abilities. The effectiveness, cellular penetration and transport of drugs to the target organs, tissues or cells is the main hindrance in the diagnosis and the treatment of this disorder. The main obstacle in the drug delivery system is the presence of blood brain barrier which checks the penetration of drugs and causes side effects. Nanoparticle eases the drug delivery to the central nervous system via blood brain barrier against the conventional drug delivery. Parkinson’s disease (PD) significantly affects patients quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science, and Scopus from January 2015 at the end of 2021, with the descriptors “Parkinson’s disease” and “drug repositioning” or “drug repurposing”. Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopa minergic neurons in the substantia nigra, resulting in dopamine deficiency and motor dysfunction. While levodopa (L- DOPA) re mains the gold standard for symptomatic treatment, its long- term administration is associated with complications such as motor fluctuations, dyskinesia, and oxidative stress. Given these limitations, interest has grown in plant- derived bioactive compounds for their potential neuroprotective and disease- modifying effects. KEYWORDS: Neurodegenerative disorder, Blood Brain Barrier, Nanoparticles, Nanotechnology. Drug repositioning, Drug repurposing, Parkinson’s disease, Nanoparticles, Nanocarriers, Pharmaceutical nanotechnology
Fields of Study & Subjects
Nanoparticle-Based Drug Delivery
Parkinson's Disease Mechanisms and Treatments
Advanced Drug Delivery Systems
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 26 March 2026
- Language
- EN
- Document type
- Book